The FDA has granted approval for Eli Lilly’s weight-loss drug Zepbound® (tirzepatide) as the first and only prescription medication specifically aimed at treating moderate-to-severe obstructive sleep apnea in adults with obesity. This landmark decision expands the therapeutic use of Zepbound, making it a significant advancement for patients suffering from this sleep disorder. The approval signifies a turning point in the treatment of obstructive sleep apnea, potentially offering an alternative to traditional interventions like CPAP machines or surgery.